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The 50% curative dose (CDS,) values were calculated on the basis of the presence or absence of C. albicans in cultures prepared from the kidneys of animals that succumbed during the experimental period or were sacrificed at the termination of the experiments. Overall, when graded doses of AB were administered in the presence of a constant, inactive dose of 5-FC (approximately one-half to one-fourth the CD50 of 5-FC), the CD50 values for AB were lower than those for amphotericin B alone. Similarly, the CD50s for 6-FC were reduced when AB was administered at a constant dose equal to one-half to one-fourth the CD50 of AB alone. In no instance was there evidence of antagonism.
Amphotericin B (AB) has long been considered the drug of choice for the treatment of systemic mycoses. However, it must be administered intravenously, and therapy must be continued over a long period. Long-term treatment is limited by the development of renal damage which may necessitate discontinuation of therapy before cure is obtained (11) .
The fluorinated pyrimidine, 5-fluorocytosine (5-FC), has been found effective in the treatment of systemic candidiasis, cryptococcal meningitis, and certain other fungal infections (4, 6, 12, 13, (15) (16) (17) (18) (19) (20) . It has the advantage of oral administration and produces few toxic effects. Furthermore, it has proved effective in some patients who failed to respond to AB (4, 19) . However, in some cases, the organisms develop resistance to 5-FC and relapse occurs (1, 2, 18) .
The use of combinations of two antimicrobial agents to increase therapeutic effectiveness has proved advantageous in antibacterial therapy (3, 7, 8, 21) . It, therefore, seemed of interest to determine the effect of combinations of AB and 5-FC in the treatment of experimental, systemic Candida albicans infections in mice. The present paper reports the results of such studies.
MATERIALS AND METHODS
The strain of C. albicans, no. 6631, employed in the experiments is the same strain used in our previous studies with 5-FC (5). Mice weighing 18 to 20 g were preconditioned with cortisone (100 mg per kg per day in two divided doses injected intramuscularly on the day before and on the day of infection). The animals were infected by the intravenous injection of 0.5 ml of a saline suspension of C. albicans containing 100,000 cells/ml.
The experiments were designed in a "checkerboard" fashion so that graded concentrations of AB administered by one route, intraperitoneally (i.p.), subcutaneously (s.c.), or orally (p.o.), to groups of eight mice per dose were tested alone and in the presence of a range of concentrations of 5-FC administered by the same or a different route (i.p., s.c., p.o., or in the diet) and vice versa. Treatment was begun on the day of infection and continued once daily for 21 days except that, when 5-FC was administered in the diet, the mice were allowed to feed ad libitum. Cultures were prepared from the kidneys of mice that died during the experimental period and from those sacrificed at the termination of the experiments on the 22nd day after infection. Experience has shown that mice pretreated with cortisone and infected intravenously with C. albicans die in 3 to 20 days with an average death rate of 7 to 10 days. By day 3, the infection is localized in the kidneys, and the organisms can be demonstrated in contact cultures of the bisected organs. Because 
